DB19188InvestigationalCell transplant therapies
Cenplacel-L is under investigation in clinical trial (Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke) for the treatment of patients with...
- Also known as
- ALLOGENEIC-UNRELATED PLACENTA-DERIVED STROMAL CELLS, EXPANDED EX VIVO · Cenplacel · CENPLACEL-L COMPONENT OF PDA-001 · CENPLACEL-L COMPONENT OF PDA-002 · HUMAN PLACENTA-DERIVED ADHERENT (PDA) CELLS THAT ARE CULTURE-EXPANDED, UNDIFFERENTIATED MESENCHYMAL-LIKE CELLS DERIVED FROM FULL-TERM PLACENTAL TISSUE. CELLULAR IDENTITY: MESENCHYMAL-LIKE STROMAL CELL: CD34-, CD10+, CD105+, AND CD200+.
Resolves to
Compound
What you can answer from here — as of October 29, 2025
Which companies are running trials of Cenplacel-L, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account